WSGR logoWSGR logo
WSGR logo
  • Experience
  • People
  • Insights
  • About Us
  • Careers

  • Practice Areas
  • Industries

  • Corporate
  • Intellectual Property
  • Litigation
  • Patents and Innovations
  • Regulatory
  • Technology Transactions

  • Capital Markets
  • Corporate Governance
  • Corporate Life Sciences
  • Derivatives
  • Emerging Companies and Venture Capital
  • Employee Benefits and Compensation
  • Energy and Climate Solutions
  • Executive Advisory Program
  • Finance and Structured Finance
  • Fund Formation
  • Greater China
  • Mergers & Acquisitions
  • Private Equity
  • Public Company Representation
  • Real Estate
  • Restructuring
  • Shareholder Engagement and Activism
  • Tax
  • U.S. Expansion

  • Special Purpose Acquisition Companies (SPACs)

  • Environmental, Social, and Governance

  • AI and Data Center Infrastructure
  • Energy Regulation and Competition
  • Project Development and M&A
  • Project Finance and Tax Credit Transactions
  • Sustainability and Decarbonization
  • Transportation Electrification

  • U.S. Expansion Library and Resources

  • Post-Grant Review
  • Trademark and Advertising

  • Antitrust Litigation
  • Arbitration
  • Board and Internal Investigations
  • Class Action Litigation
  • Commercial Litigation
  • Consumer Litigation
  • Corporate Governance Litigation
  • Employment Litigation
  • Government Investigations
  • Internet Strategy and Litigation
  • Patent Litigation
  • Securities Litigation
  • State Attorneys General
  • Supreme Court and Appellate Practice
  • Trade Secret Litigation
  • Trademark and Copyright Litigation
  • Trial
  • White Collar Crime

  • Advertising, Promotions, and Marketing
  • Antitrust and Competition
  • Committee on Foreign Investment in the U.S. (CFIUS)
  • Communications
  • Data, Privacy, and Cybersecurity
  • Export Control and Sanctions
  • FCPA and Anti-Corruption
  • Federal Trade Commission
  • Fintech and Financial Services
  • Government Contracts
  • Healthcare and FDA Regulatory
  • National Security and Trade
  • Payments
  • State Attorneys General
  • Strategic Risk and Crisis Management
  • Tariffs, Customs, and Import Compliance

  • Antitrust and Intellectual Property
  • Antitrust Civil Enforcement
  • Antitrust Compliance and Business Strategy
  • Antitrust Criminal Enforcement
  • Antitrust Litigation
  • Antitrust Merger Clearance
  • European Competition Law
  • Third-Party Merger and Non-Merger Antitrust Representation

  • FDA Regulatory and Compliance

  • Anti-Money Laundering
  • Foreign Ownership, Control, or Influence (FOCI)
  • Team Telecom

  • AI in Healthcare
  • Animal Health
  • Artificial Intelligence and Machine Learning
  • Aviation
  • Biotech
  • Blockchain and Cryptocurrency
  • Clean Energy
  • Climate and Clean Technologies
  • Communications and Networking
  • Consumer Products and Services
  • Data Storage and Cloud
  • Defense Tech
  • Diagnostics, Life Science Tools, and Deep Tech
  • Digital Health
  • Digital Media and Entertainment
  • Electronic Gaming
  • Fintech and Financial Services
  • FoodTech and AgTech
  • Global Generics
  • Internet
  • Life Sciences
  • Medical Devices
  • Mobile Devices
  • Mobility
  • NewSpace
  • Quantum Computing
  • Semiconductors
  • Software

  • Offices
  • Country Desks
  • Events
  • Community
  • Our Diversity
  • Sustainability
  • Our Values
  • Board of Directors
  • Management Team

  • Austin
  • Boston
  • Boulder
  • Brussels
  • Century City
  • Hong Kong
  • London
  • Los Angeles
  • New York
  • Palo Alto
  • Salt Lake City
  • San Diego
  • San Francisco
  • Seattle
  • Shanghai
  • Washington, D.C.
  • Wilmington, DE

  • Law Students
  • Judicial Clerks
  • Experienced Attorneys
  • Patent Agents
  • Business Professionals
  • Alternative Legal Careers
  • Contact Recruiting
Insights
Type
People
Practices
Industries
From Date
To Date
Reset Search

Search Results

Client Highlights

6.24.26

Wilson Sonsini Advises Saturnus Bio on Strategic Collaboration with Merck KGaA, Darmstadt, Germany
On June 23, 2026, Merck KGaA, Darmstadt, Germany, a leading global science and technology company, announced a strategic collaboration with Versant Ventures to launch Saturnus Bio, a next-generation precision cardiology company that utilizes targeted gene modulation to address rare mono-genetic cardiomyopathies with significant unmet need. Wilson Sonsini Goodrich & Rosati advised Saturnus Bio on the transaction.

The research-stage partnership entails a build-to-buy deal structure, including an upfront payment of $50 million from Merck KGaA, Darmstadt, Germany to fund Saturnus Bio’s research activities, securing a minority equity stake in the company, as well as additional success-based preclinical milestones, supporting the development of novel drug candidates for genetic cardiomyopathy patients. Merck KGaA, Darmstadt, Germany has exclusive rights to acquire Saturnus Bio for a pre-determined option payment, in addition to success-based earnouts.

The Wilson Sonsini team that advised Saturnus Bio on the transaction includes:
News Articles

6.04.26

Wilson Sonsini Practices, Attorneys Recognized in 2026 Chambers USA Guide
The 2026 Chambers USA guide has recognized Wilson Sonsini Goodrich & Rosati as a leading law firm in 44 geography-specific practice categories and named 87 Wilson Sonsini attorneys among the best in their fields. This year, the firm received four new practice area rankings, including in the nationwide National Security and Capital Markets: Convertible Debt categories, and three improved practice area rankings.
Client Highlights

6.02.26

Wilson Sonsini Advises Contentful on Acquisition by Salesforce
On June 1, 2026, Salesforce, the world's No. 1 AI CRM, announced that it has signed a definitive agreement to acquire Contentful, a leading composable content platform trusted by over 4,800 of the world’s leading brands to deliver personalized digital experiences at scale. Wilson Sonsini Goodrich & Rosati advised Contentful on the transaction.
Client Highlights

6.01.26

Firm Advises Edgewise Therapeutics on Its Sale of Sevasemten for up to $2.65 Billion
On June 1, 2026, Edgewise Therapeutics, a leading muscle disease biopharmaceutical company, announced that it has entered into a definitive agreement under which Servier, an independent international pharmaceutical group governed by a foundation, will acquire sevasemten, an orally administered fast skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies, and Edgewise's muscular dystrophy business for $1.55 billion in upfront cash consideration and up to $1.1 billion in additional milestone payments, for aggregate potential consideration of up to $2.65 billion. The transaction strengthens Edgewise’s balance sheet, providing enhanced financial flexibility and sharpening the company’s strategic focus to accelerate and unlock the full potential of its cardiovascular pipeline. Wilson Sonsini Goodrich & Rosati advised Edgewise on the transaction.
Client Highlights

4.10.26

Wilson Sonsini Advises Canva on Acquisition of Ortto
On April 8, 2026, Canva, the world’s leading visual communication platform, announced the acquisition of Ortto, a customer data and marketing automation company, as part of its continued investment in artificial intelligence and marketing infrastructure. Wilson Sonsini Goodrich & Rosati advised Canva on the transaction.

Ortto combines a customer data platform with powerful marketing automation, enabling teams to design and orchestrate journeys across email, SMS, push notifications, in-app messaging, forms, and surveys, all within a single system. Canva’s acquisition of Ortto strengthens Canva Grow and builds on Canva’s recent additions of MagicBrief, MangoAI, and Doohly, accelerating its ability to power the full marketing and content lifecycle, from ideation and creation through to deployment, measurement, and optimization.
Client Highlights

4.08.26

Firm Advises Katana on Its Acquisition of IDEX
On March 23, 2026, Katana, a DeFi blockchain built around a tightly integrated trading stack, announced it has completed the acquisition of IDEX, a decentralized exchange and on-chain trading infrastructure team, and launched Katana Perps, a native perpetual futures platform. Katana was incubated by Polygon and GSR Markets. Wilson Sonsini Goodrich & Rosati advised Katana on the transaction.
Client Highlights

4.08.26

Wilson Sonsini Advises Sportsbox on Acquisition by Investor Group Led by Bryson DeChambeau
On April 7, 2026, a group of investors led by professional golfer Bryson DeChambeau announced its acquisition of Sportsbox AI, a leader in kinematic AI technology and 3D motion capture for coaching and training across mobile sports and fitness applications. Wilson Sonsini Goodrich & Rosati advised Sportsbox on the transaction.
Client Highlights

4.06.26

Wilson Sonsini Advises Soleno Therapeutics on $2.9 Billion Acquisition by Neurocrine
On April 6, 2026, Neurocrine Biosciences and Soleno Therapeutics announced that Neurocrine has entered into a definitive agreement to acquire Soleno for $53.00 per share in cash, representing a total transaction equity value of $2.9 billion. Wilson Sonsini Goodrich & Rosati is advising Soleno on the transaction.
Alerts

3.03.26

Reporting Season Alert: Five Key Considerations for Proxy Season
With the 2026 proxy season upon us, companies are finalizing annual meeting materials against a backdrop of shifting investor priorities, evolving engagement dynamics, and regulatory uncertainty. This alert highlights governance, disclosure, and engagement considerations for companies preparing for their 2026 annual meetings.1 Below are five key considerations as you finalize preparations.
Client Highlights

2.25.26

Wilson Sonsini Represents Google in Acquisition of ProducerAI
On February 24, 2026, Google announced its acquisition of ProducerAI, a platform that allows users to create and refine music using generative AI. Wilson Sonsini Goodrich & Rosati represented Google in the transaction.
Client Highlights

2.23.26

Firm Advises Arcellx on $7.8 Billion Acquisition by Gilead
On February 23, 2026, Gilead Sciences announced that it has entered into a definitive agreement to acquire Arcellx, a biotechnology company focused on delivering a new class of innovative immunotherapies for patients with cancer and other incurable diseases, for $115 per share in cash at closing and one contingent value right of $5 per share, which represents an implied equity value of $7.8 billion payable at closing. Wilson Sonsini Goodrich & Rosati advised Arcellx on the transaction.
Client Highlights

2.19.26

Wilson Sonsini Advises Griptape on Acquisition by Foundry
On February 18, 2026, Foundry, a leading developer of creative software for the media and entertainment industry, announced the completion of its acquisition of Griptape, a pioneer in enterprise-grade AI orchestration. Wilson Sonsini Goodrich & Rosati advised Griptape on the transaction.

As described by Foundry, the acquisition accelerates Foundry's AI strategy, adding critical orchestration capabilities to complement the AI-powered features in Foundry's product portfolio. It represents the next evolution of this strategy, enabling studios to orchestrate multiple AI models and agents within secure, professional workflows that connect seamlessly with Foundry's existing creative toolsets. As studios shift from experimentation to everyday production use, the need for better control of AI models has become critical. Griptape enables controlled access to rapidly evolving open-source and commercial AI models in a user-friendly framework, while balancing the strict security and traceability required by major production environments.
  • 1
  • 2
  • 3
  • 4
  • people
  • insights
  • about us
  • careers
  • Binder
  • Alumni
  • Mailing List Signup
  • Client FTP Portal
  • Privacy Policy
  • Terms of Use
  • Accessibility
WSGR logo
Twitter
LinkedIn
Facebook
Instagram
Youtube
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.